TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03802721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose (50 ng) (5.4 nCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brussels sprouts before 50 ng dose
Description: Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIM supplement before 50 ng dose
Description: DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
Study: NCT01817257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Description: Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
Study: NCT01662089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg Chelate zinc supplement
Description: 15 mg Chelate zinc additional to standard 5% minoxidil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug supplement
Description: Placebo drug instead of Zinc supplement
Study: NCT02300129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo
Description: Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo
Description: Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47
Description: Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
Description: Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.
Study: NCT05048290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Participate in communication workshops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication Skills Training
Description: Participate in generic communication skills workshops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Develop a video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study: NCT00740805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT03530449

Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography

Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
Study: NCT01198158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03744650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4Heart programme
Description: A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation
Study: NCT02083276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinamhydrochlorid
Description: PO 400 mg x3 for 7 days
Study: NCT04079023

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy
Description: Subtotal vertical gastrectomy
Study: NCT02861170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Intervention
Description: In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
Study: NCT02521129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy Track Ablator (STARmed, Goyang, Korea)
Description: After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
Study: NCT03361501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre
Description: 4 x 1 g capsules administered orally once daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Study: NCT01217606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Description: One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Description: One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
Study: NCT00638872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide
Description: 3 times a week perilesional or intramuscular injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: same as PDRN
Study: NCT04298411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Falcon
Description: The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
Study: NCT02432807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1.1%
Description: Vancomycin hydrochloride ophthalmic ointment 1.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02560766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 300 mg
Description: HORIZANT 300 mg once daily
Study: NCT02079727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chondroitin sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03023748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Paricalcitol
Description: Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
Study: NCT00384956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT04398901

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
Study: NCT02560766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 600 mg
Description: HORIZANT 600 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT02397837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Up to 4.5mg, PO, (by mouth) per day of the 12-week study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo match study drug
Study: NCT01002105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen 50mg per day for 12 weeks and psychosocial intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: psychosocial intervention and placebo for 12 weeks
Study: NCT05791110

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal pancreatic elastase 1 test
Description: Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
Study: NCT02953093

Intervention type: DRUG
Group type: OTHER
Intervention: Acarbose
Description: see arm description

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: See arm description

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: See arm description
Study: NCT02746081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1436032
Description: The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
Study: NCT02653014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Study: NCT00398398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin, Cetuximab
Description: Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Study: NCT00895973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stirrups delivery vs bed delivery
Description: Position of legs at time of vaginal delivery (bed vs stirrups)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stirrups delivery vs bed delivery
Description: Position of legs at time of vaginal delivery (bed vs stirrups)
Study: NCT00696085

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief motivational intervention
Description: The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
Study: NCT02169895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg
Study: NCT01702116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extralevator APR
Description: Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive.
Study: NCT02169895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg
Study: NCT01295346

Intervention type: OTHER
Intervention: Head CT scan and blood draw
Study: NCT04240756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
Study: NCT01702116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APR
Description: standard Abdominoperineal Resection For Rectal Adenocarcinoma
Study: NCT02760251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romiplostim
Study: NCT03492164

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]FluorThanatrace ([18F]FTT)
Description: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
Study: NCT01689558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombine Endostatin
Description: Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
Study: NCT04665232

Intervention type: DRUG
Intervention: aqueous subcutaneous progesterone
Description: 25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
Study: NCT02665936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine will be given epidurally and the duration of analgesia will be calculated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and levobupivacaine
Description: dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine and Dexamethasone
Description: dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
Study: NCT04753112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
Study: NCT00364793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)
Study: NCT03421548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeMate
Description: Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.